• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice

    2020-07-10 07:10:12LakshiniHeratNatalieWardAaronMagnoElizabethRakoczyMarcioKiuchiMarkusSchlaichVanceMatthews
    World Journal of Gastroenterology 2020年23期

    Lakshini Y Herat, Natalie C Ward, Aaron L Magno, Elizabeth P Rakoczy, Marcio G Kiuchi, Markus P Schlaich,Vance B Matthews

    Abstract

    Key words: Sodium glucose co-transporter inhibitors; Sodium glucose co-transporter 2;Diabetes; Diabetic retinopathy; Mouse; Gut microbiota; Empagliflozin; Dapagliflozin;Succinate; Akimba

    INTRODUCTION

    The gut microbiome plays an important role in physiology, the immune system development and digestion[1]. Microbial richness and the metabolic capacity of the microbiome is an indicator of health status. Most of the microbiota reside in the gut.This accounts for > 5 million genes and > 1000 species, which consists of a small number of phyla[1,2]. In addition, the large diversity and complexity of the microbiota can be divided into clusters of living organisms based on their ecosystem[1,3].

    In recent years, the area of gut microbiome research has significantly increased in both human and murine studies. These studies highlight that changes in the gut microbiome and gut dysbiosis play a critical role in susceptibility to numerous diseases[4]. Although, it is widely accepted that diabetes and its complications are multifactorial, recent studies emphasise the importance of perturbations in the gut microbiota as a factor in the pathogenesis of diabetes[5-9]and its complications[10,11]. The mechanisms leading to an altered gut microbiota and gut dysbiosis during diabetes is associated with altered glycaemic control, obesity and insulin resistance, increased inflammation, oxidative stress and vascular permeability[12]. Interestingly, more studies are now focusing on the gut microbiome as a potential source of biomarkers of diabetes and its complications[13].

    Sodium glucose co-transporter 2 inhibitors (SGLT2) are oral medications for the treatment of type 2 diabetes (T2D). This drug class blocks SGLT2 in the renal proximal tubules, thereby facilitating glucosuria and subsequently reduced plasma glucose levels and improved glycaemic parameters. The SGLT2 inhibitors canagliflozin,empagliflozin and dapagliflozin have been shown to decrease glycosylated haemoglobin levels, fasting glucose levels, body weight and blood pressure[14-17].Furthermore, SGLT2 inhibitors target two of the main problems of diabetes which are cardiovascular disease (CVD) and renal disease[15,17]. SGLT2 inhibitor related studies are currently underway in the field of type 1 diabetes (T1D)[18-20]. Given the limited understanding of SGLT2 inhibition and its beneficial effects on T1D, further preclinical studies are urgently needed. The objective of our investigation was to examine the effects of two independent SGLT2 inhibitors on gut health of a highly relevant mouse model of T1D and its complications.

    MATERIALS AND METHODS

    Animals

    Specific pathogen free 10-wk-old male C57BL6/J, Kimba, Akita and Akimba mice[21-25]were obtained from the Animal Resources Centre (ARC, Perth, Australia). All experimental and animal handing activities were performed at the Harry Perkins Institute for Medical Research animal holding facility (Perth, Western Australia)according to the guidelines of the Institutional Animal Care and Use Committee.Animal ethics approval (AE141/2019) was received from the Harry Perkins Institute for Medical Research Animal Ethics Committee.

    All mice were acclimatised for seven days. Mice were housed under a 12 h light/dark cycle, at 21 ± 2°C and were given a standard chow diet (Specialty Feeds,Glen Forrest, WA, Australia) with free access to food and drinking water containing the SGLT2 inhibitor (dapagliflozin or empagliflozin; Ark Pharma Scientific Limited,China; 25 mg/kg) or vehicle dimethylsulfoxide. Mice underwent treatment for a period of 8 wk. Drinking water containing the SGLT2 inhibitor or vehicle was freshly prepared and replaced on a weekly basis. The specific number of animals per treatment group is as follows: (1) C57BL6/J:n= 7 for vehicle;n= 5 for dapagliflozin;n= 4 for empagliflozin; (2) Kimba:n= 5-6 for vehicle;n= 6 for dapagliflozin;n= 7 for empagliflozin; (3) Akita:n= 7 for vehicle;n= 6 for dapagliflozin;n= 3 for empagliflozin; and (4) Akimba:n= 2-3 for vehicle;n= 3 for dapagliflozin;n= 3 for empagliflozin.

    Tissue and serum sample collection

    At the end of the experiment, mice were deeply anesthetised using isoflurane inhalation. Blood samples were collected using cardiac puncture and placed on ice immediately. Samples were centrifuged, serum was collected and stored at -80 °C for subsequent experiments. Mice were sacrificed, the cecum content and kidneys were collected, snap frozen and stored at -80°C for subsequent experiments. Pancreatic tissue was collected and fixed for 24 h in 10% buffered formalin for histology.

    Succinate and short chain fatty acid analysis

    The concentration of succinate and the short chain fatty acid (SCFA) butyric acid was measured in serum using gas chromatography-mass spectrometry as previously described[26,27]. Data were calculated in μmol/L units.

    Pancreatic tissue histology and digital imaging

    Upon fixation and processing in 70% ethanol overnight, pancreatic tissue was paraffin-embedded and sectioned at 5 μm thickness using a Leica semi-automated RM2245 microtome (Leica Biosystems, Sydney, Australia). Sections were stained with Gill’s hematoxylin (Sigma-Aldrich, Sydney, Australia) and alcoholic eosin (Sigma-Aldrich New South Wales, Australia) for the analysis of pancreatic histology. Tissue sections were visualised and imaged using the inverted Nikon Eclipse Ti microscopic system (Nikon, Tokyo, Japan) and a CoolSNAP HQ2 digital camera (Photometrics,Tucson, AZ, United States). Image analysis was conducted using NIS-Elements Advanced Research software (Nikon, Tokyo, Japan).

    Insulin enzyme-linked immunosorbent assay

    Serum insulin was determined using a rat/mouse Insulin enzyme-linked immunosorbent assay (ELISA) (Millipore, Australia; EZRMI-13K) according to the manufacturer instructions.

    ELISA for leptin

    Mouse serum was diluted 1 in 20 and leptin concentrations were determined by Mouse/rat leptin ELISA kit following manufacturer instructions (Quantikine ELISA;Mouse/rat leptin immunoassay; R&D Systems; Minneapolis, MN, United Sates;MOBOO).

    ELISA for norepinephrine

    Frozen mouse kidney tissue was homogenized on ice in phosphate buffered saline containing cOmplete?, ethylenediaminetetraacetic acid-free protease inhibitor cocktail (Merck, Victoria, Australia) at 10 μL per 1 mg of tissue. Debri free supernatant was analysed for norepinephrine content according to manufacturer instructions(Mouse Norepinephrine NA ELISA Kit; Cusabio, China; CSB-E07870m).

    Statistical analysis

    The number of mice required was determined with the assistance of Mrs Sally Burrows (Biostatistician, Royal Perth Hospital). Data was analysed using a two-tailed Student'sttest. Quantitative data is presented as mean ± SE. Data was deemed significant whenP< 0.05. Graphs were produced with GraphPad Prism 8 (GraphPad Software Inc., CA, United States).

    RESULTS

    Type 1 diabetes promotes hypoinsulinemia and pancreatitis in Akita and Akimba mice

    In our studies, we used 4 strains of mice. We used C57BL/6J mice as our wild-type strain. The Kimba (VEGF+/+) mouse model possesses transient overexpression of human vascular endothelial growth factor (hVEGF) in photoreceptors and hence,displays changes associated with diabetic retinopathy (DR) but lacks the hyperglycaemic background. The Akita (Ins2Akita) mouse is a T1D model that possesses a dominant mutation in the Mody4 locus in theinsulin 2gene. Male heterozygous mice possess hyperglycaemia and features of DR. The insulin protein is incorrectly folded in Akita mice and this results in β-cell toxicity. By crossing Akita and Kimba mice, the Akimba (Ins2AkitaVEGF+/-) mouse model is generated where the interplay between high blood glucose levels and VEGF-induced pathology can be investigated in diabetic complications such as DR. Insulin destruction and a concomitant reduction in insulin production is a hallmark of T1D. As predicted, the Akita allele in the Akita and Akimba mice conferred hypoinsulinemia compared to C57BL/6J and Kimba mice (Figure 1). In agreement with the higher insulin levels,islets were frequently observed in pancreata from C57BL/6J (Figure 2A) and Kimba mice (Figure 2B). However, islets were observed less frequently in Akita (Figure 2C)and Akimba mice (Figure 2D). In addition, apoptotic bodies were observed in the islets of Akita mice (Figure 2C). The acinar cells of Akita (Figure 2C) and Akimba(Figure 2D) mice appeared swollen which is indicative of acute injury or pancreatitis.These cells possessed high levels of eosin staining.

    SGLT2 inhibition influences the main products and intermediate metabolites of gut metabolism in Akita and Akimba mice

    Succinate is an intermediate metabolite of gut metabolism and has been shown to be a pathogenic factor in DR[28-30]. We hypothesised that SGLT2 inhibition may reduce the levels of this pathogenic factor in Akimba mice which develop DR. We did indeed demonstrate that dapagliflozin significantly reduced succinate levels (Figure 3A) and empagliflozin suppressed succinate levels (Figure 3B).

    The main products of gut metabolism are SCFAs. We examined levels of the beneficial SCFA butyric acid and observed that levels were significantly increased in Akita mice treated with dapagliflozin and mildly elevated with empagliflozin therapy(Figure 3C).

    Figure 1 lnsulin dysregulation prevails in mice with type 1 diabetes. Serum insulin levels are reduced in Akimba and Akita mice. n = 3-8 mice/group. All data represented as mean ± SE.

    SGLT2 inhibition with dapagliflozin and empagliflozin reduces activation of the sympathetic nervous system in type 1 diabetic mice

    Our previously published findings have uncovered that one of the mechanisms by which SGLT2 inhibition imparts metabolic benefits is by reduced activation of the sympathetic nervous system (SNS)[31,32]. Levels of the major neurotransmitter of the sympathetic system, norepinephrine, were measured in the kidneys of our T1D mice.Consistent with our previously published work, SNS activation as evidenced by norepinephrine content, was significantly reduced with both dapagliflozin and empagliflozin therapy in Akita mice (Figure 4A). Norepinephrine content was also significantly reduced after empagliflozin treatment of Akimba mice (Figure 4B).

    SGLT2 inhibition promotes hypoleptinemia in non-diabetic C57BL/6J and Kimba mice

    As leptin is a metabolically beneficial adipokine, we examined the impact of SGLT2 inhibition on serum leptin levels. Previous studies have shown that SGLT2 inhibition may reduce serum leptin levels[33]. Interestingly, C57BL/6J mice also displayed significantly reduced serum leptin after empagliflozin treatment and reduced leptin after dapagliflozin therapy (Figure 5A). Kimba mice also possessed significantly reduced serum leptin after dapagliflozin treatment (Figure 5B) and suppressed leptin levels after empagliflozin therapy (Figure 5C). The inhibition of SGLT2 failed to influence leptin levels in Akita and Akimba mice.

    DISCUSSION

    Inhibition of SGLT2 in the kidney is a therapeutic approach to improve glucose homeostasis in diabetic patients. The clinical trial known as the EMPA-REG OUTCOME study has shown that the SGLT2 inhibitor, empagliflozin, increased glycaemic control and significantly reduced the progression of renal disease[15]. In addition, empagliflozin promoted a substantial 38% relative risk reduction in death from cardiovascular causes[17]. To date, the number of studies assessing the impact of SGLT2 inhibition on T1D and its complications including DR in preclinical and human cohorts is limited[34]. In our current study, we aimed to assess whether SCFAs and intermediate metabolites of gut metabolism may be influenced by SGLT2 inhibition in a mouse model of T1D and its complications. Furthermore, we attempted to uncover mechanisms by which SGLT2 inhibitors may impact the progression of disease in our mouse models.

    Figure 2 Acute pancreatic injury in Akita and Akimba mice. A: Representative pancreatic images of C57BL/6J mice; B: Representative pancreatic images of Kimba mice; C: Representative pancreatic images of Akita mice; D: Representative pancreatic images of Akimba mice. Black arrows indicate islets; Yellow arrows and dotted outline indicates swollen acinar cells and orange arrows indicate apoptotic bodies in islets; Scale bar = 100 μm.

    There is great interest in the role the gut microbiome plays in the metabolic syndrome and T2D[27]. Many chronic diseases including diabetes demonstrate altered bacterial composition[35], which may influence glucose metabolism and development of diabetic complications such as retinopathy[10,36]. SCFAs are a product of the gut microbiota. These products include acetate and butyric acid and contribute to immune and inflammatory responses, as well as control of lipid and glucose homeostasis. Studies from our group and others indicate that numerous drug classes alter the gut microbiome[26,37]. Additionally, a reduction in SCFA production is characteristic of metabolic dysfunction. In our previous studies, we analysed caecal SCFAs from dapagliflozin and vehicle treated hypertensive mice and demonstrated that SGLT2 inhibition results in an increase in the levels of acetate and butyric acid in hypertensive Schlager mice[31]. In a chronic kidney disease mouse model, Mishimaet al[38]also demonstrated that the SGLT2 inhibitor canangliflozin significantly increased the cecal SCFA acetate, propionate and butyrate. Our previous data highlighted a potentially advantageous impact of SGLT2 inhibition on the microbiome.Additionally, as our results were produced only after 2 wk of therapy, future studies should allow a more thorough examination of the status of the microbiome to determine whether a longer duration of therapy confers further benefits on the microbiome. In our current study, our T1D and DR mice were treated with SGLT2 inhibitors for 8 wk. We found that SGLT2 inhibition promoted beneficial changes in the metabolite succinate (Figure 3A and 3B) and the SCFA butyrate (Figure 3C).Recent findings have uncovered that dapagliflozin treatment of T2D Db/Db mice promotes increases in the beneficial bacterial speciesAkkermansia muciniphilaand reduces the Firmicutes : Bacteroidetes (F : B) ratio which is associated with a lean phenotype[39]. Our future studies will plan to assess the levels ofAkkermansia muciniphilaand the F:B ratio in our T1D and DR mouse models before and after SGLT2 inhibition.

    Succinate is an intermediate metabolite of gut metabolism that has been correlated with a worsened DR phenotype. It signals through the succinate specific receptor known as GPR91 and it has been shown that succinate may promote the angiogenic factor VEGF in retinal ganglion cells and this may promote the pathogenesis of DR[40].Matsumoto and colleagues[29]demonstrated that vitreous levels of succinate were elevated in human subjects with active proliferative DR. In our novel Akimba mouse model which reproducibly presents with DR[21], SGLT2 inhibition with both dapagliflozin (Figure 3A) and empagliflozin (Figure 3B) lowered serum succinate levels. It would be interesting to measure vitreous succinate and VEGF levels in our mice in future studies. In addition, it would be mechanistically insightful to assess GPR91 expression in the eyes of all mouse strains before and after SGLT2 inhibition as GPR91 and SGLT2 (unpublished data) are both expressed in retinal ganglion cells.

    Figure 3 The diabetic retinopathy pathogenic metabolite, succinate, is downregulated with sodium glucose co-transporter 2 inhibition in Akimba mice. A:Serum succinate levels in Akimba mice treated with dapapagliflozin; B: Serum succinate levels in Akimba mice treated with empagliflozin; C: Serum levels of the beneficial short chain fatty acid, butyric acid, are elevated in diabetic Akita mice with sodium glucose co-transporter 2 inhibition. n = 3-7 mice/group for all groups except for control Akimba (Figure 3B) where n = 2; aP < 0.03; Data represented as mean ± SE.

    Hyperactivation of the SNS is characteristic of many metabolic diseases such as obesity and T2D[41,42]. Our team previously studied the impact of SGLT2 inhibition on SNS activation[31,32]. We were the first to demonstrate in human proximal tubular cells and mouse models of obesity and neurogenic hypertension that: (1) Activation of the SNSviaincreased secretion of norepinephrine up-regulates SGLT2 protein levels and promotes SGLT2 translocation to the cell membrane; (2) Treatment of mice with a high fat diet and the SGLT2 inhibitor dapagliflozin promotes glucosuria, decreased weight gain and facilitated better glucose control; and (3) SGLT2 inhibition reduced SNS innervation in the kidney and the heart. Our data suggests that SGLT2 expression is upregulated by the major neurotransmitter of the SNS and that SGLT2 inhibition promotes sympatho-inhibition. Excitingly, we also now show that SGLT2 inhibition is once again sympathoinhibitory in our T1D and DR mouse models (Figure 4).

    It appears that dapagliflozin was more bioactive than empagliflozin when it comes to the effects on succinate levels (Figure 3A and B). It has been shown in mouse models that dapagliflozin is superior to empagliflozin as it has an increased half-life,longer duration of action, higher distribution and long retention period in the kidney[43]. Therefore, this could be the likely reasoning for the dapagliflozin being more bioactive in relation to succinate levels.

    Interestingly, empagliflozin was able to reduce norepinephrine levels to a greater degree compared to dapagliflozin in diabetic Akita mice (Figure 4A). This is interesting in the context of the EMPA-REG study[17]. In this study, factors driven by an increased SNS such as mortality from CVD were reduced to a markedly greater degree compared to the dapagliflozin DECLARE-TIMI 58 clinical trial[44]. Hence,regulation of the SNS may be one factor where empagliflozin may be specifically more effective than dapagliflozin.

    The activation status of the SNS in T1D is currently quite controversial. It has been shown that there was a reduction in islet selective sympathetic nerves in human T1D pancreata isolated during autopsy compared to non-diabetic controls[45]. On the other hand, it has been demonstrated that children with T1D have a higher incidence of postural orthostatic tachycardia syndrome which is associated with sympathetic overactivity[46,47]. Our study conclusively shows that SGLT2 inhibition reduced levels of norepinephrine in our T1D and DR mouse models.

    We assessed serum levels of the adipokine leptin in our mice treated with SGLT2 inhibitors or not. It was clear that leptin levels were reduced with SGLT2 inhibition with dapagliflozin and empagliflozin, particularly in C57BL/6J and Kimba mice(Figure 5A-C). This appears to be a common phenomenon that has been observed in response to a range of SGLT2 inhibitors which include ipragliflozin and canagliflozin[33,48]. We can conclude that the reductions in leptin were not due to reductions in body weight after SGLT2 inhibition in C57BL/6J and Kimba mice (data not shown). Reductions in leptin may also be metabolically beneficial as leptin is known to activate the SNS and may impair pancreatic β-cell function[49,50]. In future studies, we will also assess the effect of SGLT2 inhibition on other adipokines such as TNF-α and IL-6.

    We are the first study to compare and contrast the effects of SGLT2 inhibition on the main products and intermediate metabolites of gut metabolism in Akita and Akimba mice. Excitingly, our results highlighted that after SGLT2 therapy, the pathogenic biomarker succinate is reduced in our Akimba DR mouse model. Our next task is to ascertain whether our finding may be reproduced in a human DR cohort treated with the SGLT2 inhibitor empagliflozin.

    Figure 4 lnhibition of sodium glucose cotransporter 2 promotes sympathoinhibition in the kidney of diabetic Akita and Akimba mice. A: Renalnorepinephrine levels in Akita; B: Renal norepinephrine levels in Akimba mice. n = 3-7 mice/group; aP < 0.05; bP < 0.005; All data represented as mean ± SE.

    Figure 5 lnhibition of sodium glucose cotransporter 2 reduces serum leptin levels. A: Serum leptin levels in C57BL/6J. B: Serum leptin levels in Kimba mice treated with dapagliflozin. C: Serum leptin levels in Kimba mice treated with empagliflozin. n = 4-7 mice/group; aP < 0.05; All data represented as mean ± SE.

    ARTICLE HIGHLIGHTS

    In comparison to C57BL/6J and Kimba mice, both Akita and Akimba mice showed reduced levels of insulin production due to the presence of the Akita allele. In line with this, Akita mice also showed the presence of apoptotic bodies within the pancreatic islets and the acinar cells of both the Akita and Akimba mice displayed swelling which is suggestive of acute injury or pancreatitis. In Akimba mice, SGLT2 inhibition with dapagliflozin for 8 wk significantly reduced succinate levels when compared to vehicle treated mice. Furthermore, succinate levels in Akimba mice treated with the SGLT2 inhibitor empagliflozin showed a similar trend. In diabetic Akita mice, the beneficial SCFA butyric acid was significantly increased after dapagliflozin treatment when compared to vehicle. There was a significant reduction in the kidney norepinephrine content in both dapagliflozin and empagliflozin treated Akita mice.Furthermore, the diabetic Akimba mice also showed a significant reduction in kidney norepinephrine content when treated with empagliflozin. Lastly, both non-diabetic C57BL/6J and Kimba mice showed significantly reduced serum leptin levels after dapagliflozin therapy.

    Research conclusions

    Our novel study compares and contrasts the effects of SGLT2 inhibition on the main products and intermediate metabolites of gut metabolism particularly in Akita and Akimba mice. We conducted studies using two independent SGLT2 inhibitors and showed that both inhibitors reduced the pathogenic biomarker succinate in our novel T1D Akimba mouse model of retinopathy. However, in relation to succinate levels in Akimba mice, dapagliflozin was more bioactive than empagliflozin, potentially due to factors such as increased half-life, longer duration of action, higher distribution and long retention period in the kidney. Furthermore, we demonstrate for the first time that SGLT2 inhibition is sympathoinhibitory in a T1D mouse model.

    Research perspectives

    In line with our findings, it would be mechanistically insightful in the future to assess the expression of the succinate specific receptor GPR91 in ocular tissue before and after SGLT2 inhibition as SGLT2 is expressed in the eye. Furthermore, it is important to determine whether our findings can be reproduced in patients with T1D and its complications who are treated with SGLT2 inhibitors.

    ACKNOWLEDGEMENTS

    The authors acknowledge Wei Ern Ong (School of Biomedical Sciences, University of Western Australia, Perth, Western Australia).

    国产精品久久久久久精品古装| 成人国产麻豆网| 亚洲精品日韩av片在线观看| 日本与韩国留学比较| 成人黄色视频免费在线看| 日本wwww免费看| 女人精品久久久久毛片| av免费在线看不卡| 欧美少妇被猛烈插入视频| 精品少妇内射三级| 韩国高清视频一区二区三区| 亚洲久久久国产精品| 亚洲精品久久久久久婷婷小说| 亚洲精品色激情综合| 99九九在线精品视频| 狠狠精品人妻久久久久久综合| 色5月婷婷丁香| 亚洲一区二区三区欧美精品| 一级二级三级毛片免费看| 中文字幕精品免费在线观看视频 | 成人综合一区亚洲| 亚洲精品一二三| 亚洲国产日韩一区二区| 中文字幕人妻熟人妻熟丝袜美| 中国美白少妇内射xxxbb| 亚洲av二区三区四区| 满18在线观看网站| 五月伊人婷婷丁香| 色吧在线观看| 美女主播在线视频| 久久久精品免费免费高清| 亚洲精品中文字幕在线视频| 久久人人爽人人片av| 蜜桃国产av成人99| 国产精品久久久久久久久免| 国产视频内射| 中文字幕制服av| 久久久国产欧美日韩av| 一区二区日韩欧美中文字幕 | 久久国内精品自在自线图片| 亚洲欧美清纯卡通| 久久久久网色| 少妇人妻精品综合一区二区| 婷婷成人精品国产| 特大巨黑吊av在线直播| 国产无遮挡羞羞视频在线观看| 亚洲欧洲日产国产| 亚洲精品亚洲一区二区| 全区人妻精品视频| 欧美日韩成人在线一区二区| 爱豆传媒免费全集在线观看| 国产免费视频播放在线视频| 久久精品夜色国产| 国产高清三级在线| 不卡视频在线观看欧美| 日本免费在线观看一区| 亚洲精品久久久久久婷婷小说| 免费人妻精品一区二区三区视频| 色网站视频免费| 看免费成人av毛片| 寂寞人妻少妇视频99o| 免费人妻精品一区二区三区视频| 国产国语露脸激情在线看| 亚洲精品国产色婷婷电影| 天堂8中文在线网| av线在线观看网站| 狂野欧美激情性bbbbbb| 中文字幕亚洲精品专区| 日韩在线高清观看一区二区三区| 亚洲中文av在线| 亚洲一区二区三区欧美精品| 精品午夜福利在线看| 一级a做视频免费观看| 九色成人免费人妻av| 有码 亚洲区| 国产亚洲午夜精品一区二区久久| √禁漫天堂资源中文www| √禁漫天堂资源中文www| a级毛片免费高清观看在线播放| 少妇的逼好多水| 九色成人免费人妻av| 激情五月婷婷亚洲| 久久午夜综合久久蜜桃| 国产精品女同一区二区软件| 黑人欧美特级aaaaaa片| 亚洲情色 制服丝袜| 午夜福利视频精品| 国产精品一区www在线观看| 蜜桃久久精品国产亚洲av| 久热这里只有精品99| 女性生殖器流出的白浆| 日韩一本色道免费dvd| 亚洲国产av新网站| 欧美国产精品一级二级三级| 青春草亚洲视频在线观看| 丰满迷人的少妇在线观看| av国产精品久久久久影院| 日本欧美国产在线视频| 中文字幕亚洲精品专区| 成人综合一区亚洲| 大香蕉久久网| 我的老师免费观看完整版| 欧美bdsm另类| 国产精品免费大片| 97在线视频观看| 在线观看免费高清a一片| 国产精品一区www在线观看| 亚洲美女搞黄在线观看| 久久婷婷青草| 久久精品人人爽人人爽视色| 欧美精品一区二区大全| 日韩伦理黄色片| a级毛片免费高清观看在线播放| 亚洲成人手机| 国产精品99久久99久久久不卡 | 性色av一级| 国产在线一区二区三区精| 免费看不卡的av| 性高湖久久久久久久久免费观看| 天堂中文最新版在线下载| 汤姆久久久久久久影院中文字幕| 十分钟在线观看高清视频www| av一本久久久久| 美女内射精品一级片tv| 麻豆精品久久久久久蜜桃| 99久久人妻综合| 亚洲国产精品999| 久久人妻熟女aⅴ| 黄片无遮挡物在线观看| 色吧在线观看| 观看美女的网站| 99久国产av精品国产电影| 亚洲国产欧美日韩在线播放| 精品人妻在线不人妻| 99视频精品全部免费 在线| 欧美人与性动交α欧美精品济南到 | av网站免费在线观看视频| 最近最新中文字幕免费大全7| 久久青草综合色| 麻豆精品久久久久久蜜桃| 在线观看免费视频网站a站| 中文字幕人妻丝袜制服| 欧美bdsm另类| 爱豆传媒免费全集在线观看| 男女高潮啪啪啪动态图| 精品久久久精品久久久| 国产欧美日韩一区二区三区在线 | 久久久久精品久久久久真实原创| 国国产精品蜜臀av免费| 午夜福利影视在线免费观看| 婷婷成人精品国产| 97超碰精品成人国产| 亚洲av欧美aⅴ国产| 亚洲一级一片aⅴ在线观看| 午夜福利视频精品| 丝袜在线中文字幕| 国产精品人妻久久久久久| 高清午夜精品一区二区三区| 69精品国产乱码久久久| 国产片内射在线| 国产片特级美女逼逼视频| 狠狠精品人妻久久久久久综合| 欧美变态另类bdsm刘玥| 99视频精品全部免费 在线| 国产欧美日韩综合在线一区二区| 狂野欧美激情性xxxx在线观看| 欧美 亚洲 国产 日韩一| 蜜桃久久精品国产亚洲av| 欧美激情国产日韩精品一区| 精品人妻偷拍中文字幕| 一级毛片 在线播放| 久久青草综合色| 久久精品久久久久久久性| 精品一品国产午夜福利视频| 日韩一区二区视频免费看| 国产在线视频一区二区| 男女啪啪激烈高潮av片| 18禁裸乳无遮挡动漫免费视频| 男男h啪啪无遮挡| 香蕉精品网在线| a级片在线免费高清观看视频| 国产免费一级a男人的天堂| 色婷婷av一区二区三区视频| 国产亚洲最大av| 一本一本综合久久| 乱人伦中国视频| 精品酒店卫生间| 亚洲熟女精品中文字幕| 黑人欧美特级aaaaaa片| 午夜激情福利司机影院| 午夜影院在线不卡| 在线天堂最新版资源| 日本午夜av视频| 综合色丁香网| 久久精品久久久久久久性| 国产午夜精品一二区理论片| 91久久精品电影网| 大码成人一级视频| 美女cb高潮喷水在线观看| 亚洲美女搞黄在线观看| 欧美+日韩+精品| 视频在线观看一区二区三区| 一边亲一边摸免费视频| 99久国产av精品国产电影| 少妇精品久久久久久久| 99国产综合亚洲精品| 日本vs欧美在线观看视频| 黄色毛片三级朝国网站| 久久99热6这里只有精品| 少妇被粗大的猛进出69影院 | 99re6热这里在线精品视频| 汤姆久久久久久久影院中文字幕| 日本猛色少妇xxxxx猛交久久| 欧美 亚洲 国产 日韩一| 天天影视国产精品| 人体艺术视频欧美日本| 日韩不卡一区二区三区视频在线| 国产av国产精品国产| 啦啦啦啦在线视频资源| 国产毛片在线视频| 街头女战士在线观看网站| 狂野欧美激情性xxxx在线观看| 国产精品久久久久久精品电影小说| 国产色婷婷99| 亚洲av日韩在线播放| 精品午夜福利在线看| 夜夜骑夜夜射夜夜干| 伊人久久国产一区二区| 大陆偷拍与自拍| 人人妻人人澡人人看| 亚洲,一卡二卡三卡| 国产精品一二三区在线看| 99国产精品免费福利视频| 久久99蜜桃精品久久| 久久人人爽av亚洲精品天堂| 超碰97精品在线观看| 伊人久久精品亚洲午夜| av免费观看日本| av在线播放精品| 丰满饥渴人妻一区二区三| 亚洲精华国产精华液的使用体验| 亚洲精品日韩在线中文字幕| 国产高清国产精品国产三级| 99热6这里只有精品| 秋霞伦理黄片| 美女大奶头黄色视频| 免费久久久久久久精品成人欧美视频 | 国产永久视频网站| 免费久久久久久久精品成人欧美视频 | 日本与韩国留学比较| 黄色怎么调成土黄色| 国产精品久久久久久久久免| 国产成人一区二区在线| 亚洲精品日韩在线中文字幕| 亚洲国产精品一区三区| 日本黄色片子视频| 欧美人与善性xxx| 欧美日韩精品成人综合77777| 国产成人免费无遮挡视频| 亚洲精品乱码久久久v下载方式| 成人亚洲欧美一区二区av| 日韩制服骚丝袜av| 亚洲精品国产av成人精品| 国产色婷婷99| 久久久亚洲精品成人影院| 九色成人免费人妻av| 亚洲精品日本国产第一区| 青春草视频在线免费观看| 免费观看在线日韩| 成人国语在线视频| 一级毛片我不卡| 国产精品麻豆人妻色哟哟久久| 国产免费福利视频在线观看| 夫妻午夜视频| 麻豆乱淫一区二区| 91精品三级在线观看| 日本午夜av视频| 一二三四中文在线观看免费高清| 亚洲国产成人一精品久久久| 成人亚洲精品一区在线观看| 日韩大片免费观看网站| 美女cb高潮喷水在线观看| 国产日韩欧美在线精品| 亚洲精品aⅴ在线观看| √禁漫天堂资源中文www| 亚洲欧美日韩另类电影网站| 国产成人一区二区在线| 欧美日韩在线观看h| 国产高清有码在线观看视频| 高清在线视频一区二区三区| 在线天堂最新版资源| 日韩中文字幕视频在线看片| 在线 av 中文字幕| 热99久久久久精品小说推荐| 国产午夜精品久久久久久一区二区三区| 日本av手机在线免费观看| 久热久热在线精品观看| 欧美人与善性xxx| 国产极品粉嫩免费观看在线 | 久久久久久人妻| 一级毛片 在线播放| 老司机亚洲免费影院| 两个人免费观看高清视频| 只有这里有精品99| 亚洲欧美日韩卡通动漫| 老熟女久久久| 我的老师免费观看完整版| 欧美另类一区| 晚上一个人看的免费电影| 亚洲经典国产精华液单| av又黄又爽大尺度在线免费看| 亚洲欧美中文字幕日韩二区| 午夜免费男女啪啪视频观看| 亚洲美女黄色视频免费看| 美女福利国产在线| 亚洲人成网站在线播| 在线天堂最新版资源| 久久人人爽人人爽人人片va| 亚洲人与动物交配视频| 不卡视频在线观看欧美| 精品久久久久久电影网| 亚洲精品日本国产第一区| 亚洲人成网站在线观看播放| 日韩av不卡免费在线播放| 亚洲av电影在线观看一区二区三区| 超碰97精品在线观看| 亚洲中文av在线| 成人国语在线视频| 午夜激情福利司机影院| 久久精品国产亚洲av涩爱| 菩萨蛮人人尽说江南好唐韦庄| 欧美 亚洲 国产 日韩一| 午夜视频国产福利| 欧美精品一区二区免费开放| 美女福利国产在线| 日本欧美视频一区| 精品人妻偷拍中文字幕| 日本爱情动作片www.在线观看| 十八禁高潮呻吟视频| 亚洲欧美精品自产自拍| 成人漫画全彩无遮挡| 嘟嘟电影网在线观看| 精品国产一区二区三区久久久樱花| 亚洲av福利一区| 天堂俺去俺来也www色官网| 成人亚洲精品一区在线观看| 在线观看三级黄色| 少妇人妻精品综合一区二区| 亚洲国产日韩一区二区| 最近最新中文字幕免费大全7| 国产乱来视频区| 大香蕉久久网| 18禁裸乳无遮挡动漫免费视频| 久久精品夜色国产| 国产成人精品福利久久| 精品久久蜜臀av无| 麻豆精品久久久久久蜜桃| .国产精品久久| 激情五月婷婷亚洲| 久久精品国产鲁丝片午夜精品| 亚洲一区二区三区欧美精品| 亚洲成人手机| 日韩在线高清观看一区二区三区| 日本wwww免费看| 97精品久久久久久久久久精品| 日本黄色日本黄色录像| 大码成人一级视频| 国产日韩欧美视频二区| 成人亚洲精品一区在线观看| 精品久久久久久久久av| 飞空精品影院首页| 日本-黄色视频高清免费观看| 搡老乐熟女国产| 极品少妇高潮喷水抽搐| 超色免费av| 亚洲av免费高清在线观看| 九草在线视频观看| 中文精品一卡2卡3卡4更新| 超碰97精品在线观看| 国产免费一级a男人的天堂| 久久97久久精品| 成年女人在线观看亚洲视频| 国产欧美日韩综合在线一区二区| a 毛片基地| videosex国产| av天堂久久9| 欧美精品高潮呻吟av久久| 观看av在线不卡| 曰老女人黄片| 成人亚洲精品一区在线观看| 男女国产视频网站| av在线app专区| 久久99蜜桃精品久久| 国产亚洲精品久久久com| 在线精品无人区一区二区三| 精品久久蜜臀av无| 午夜精品国产一区二区电影| 边亲边吃奶的免费视频| 美女福利国产在线| 国产精品人妻久久久久久| av免费在线看不卡| 亚洲国产欧美日韩在线播放| 久久久久久久久久久久大奶| 18禁在线无遮挡免费观看视频| 人人妻人人爽人人添夜夜欢视频| 五月玫瑰六月丁香| 18禁动态无遮挡网站| 久久久亚洲精品成人影院| 一区二区三区免费毛片| 99re6热这里在线精品视频| 久久久国产一区二区| 国产在线一区二区三区精| 欧美日韩在线观看h| a级毛片黄视频| 人人妻人人澡人人爽人人夜夜| 日韩av免费高清视频| 丰满饥渴人妻一区二区三| 久久人妻熟女aⅴ| 国产免费视频播放在线视频| 午夜免费男女啪啪视频观看| 免费不卡的大黄色大毛片视频在线观看| 亚洲成人一二三区av| 中文天堂在线官网| 男男h啪啪无遮挡| 午夜福利,免费看| 国产国拍精品亚洲av在线观看| 亚洲美女搞黄在线观看| 视频在线观看一区二区三区| 午夜福利影视在线免费观看| 九草在线视频观看| 久久午夜综合久久蜜桃| 精品一区二区三卡| 亚洲国产精品专区欧美| 丝袜在线中文字幕| freevideosex欧美| 五月天丁香电影| 波野结衣二区三区在线| 校园人妻丝袜中文字幕| 狂野欧美白嫩少妇大欣赏| 成人亚洲欧美一区二区av| 日韩成人av中文字幕在线观看| 考比视频在线观看| 精品久久蜜臀av无| 亚洲国产精品国产精品| 免费观看a级毛片全部| 欧美精品亚洲一区二区| 亚洲成人av在线免费| 日本爱情动作片www.在线观看| av.在线天堂| 亚洲色图综合在线观看| 久久婷婷青草| 十分钟在线观看高清视频www| 熟妇人妻不卡中文字幕| 亚洲美女黄色视频免费看| 97精品久久久久久久久久精品| 你懂的网址亚洲精品在线观看| 国精品久久久久久国模美| 少妇被粗大的猛进出69影院 | 国产永久视频网站| 在现免费观看毛片| 老司机影院毛片| av在线播放精品| 亚洲久久久国产精品| 欧美少妇被猛烈插入视频| 男女无遮挡免费网站观看| 一本色道久久久久久精品综合| 亚洲美女搞黄在线观看| 一区在线观看完整版| 国产视频内射| 视频在线观看一区二区三区| a 毛片基地| 满18在线观看网站| 热99国产精品久久久久久7| 国产熟女欧美一区二区| 久久 成人 亚洲| 日韩,欧美,国产一区二区三区| 99九九线精品视频在线观看视频| 免费看不卡的av| 欧美国产精品一级二级三级| 精品一品国产午夜福利视频| 大码成人一级视频| 国产色爽女视频免费观看| 亚洲美女视频黄频| 久久久久久久大尺度免费视频| 欧美日韩成人在线一区二区| 狂野欧美激情性bbbbbb| 欧美精品一区二区大全| 国产亚洲精品久久久com| 最近中文字幕2019免费版| 亚洲国产最新在线播放| 成人免费观看视频高清| 亚洲精品av麻豆狂野| 日本黄色日本黄色录像| 久久99热这里只频精品6学生| 亚洲国产精品999| 亚洲欧洲精品一区二区精品久久久 | 美女cb高潮喷水在线观看| 熟女电影av网| 能在线免费看毛片的网站| 久久精品人人爽人人爽视色| 久久精品久久精品一区二区三区| 精品少妇黑人巨大在线播放| 久久久久久久精品精品| 欧美激情国产日韩精品一区| 亚洲av电影在线观看一区二区三区| 热99久久久久精品小说推荐| 一级毛片电影观看| 考比视频在线观看| 91久久精品国产一区二区三区| 人妻 亚洲 视频| 免费av中文字幕在线| 两个人免费观看高清视频| 免费av中文字幕在线| 日韩欧美一区视频在线观看| 免费久久久久久久精品成人欧美视频 | 久久久久人妻精品一区果冻| av视频免费观看在线观看| 夫妻午夜视频| 国产精品国产av在线观看| 国产片内射在线| 中国美白少妇内射xxxbb| 黄片播放在线免费| 不卡视频在线观看欧美| 国产黄片视频在线免费观看| 日韩,欧美,国产一区二区三区| 亚洲精品av麻豆狂野| 欧美激情极品国产一区二区三区 | 午夜91福利影院| 精品国产露脸久久av麻豆| 欧美 亚洲 国产 日韩一| 午夜福利网站1000一区二区三区| 国产精品一区www在线观看| 亚洲激情五月婷婷啪啪| a级毛色黄片| 精品久久久久久久久av| 精品一品国产午夜福利视频| 亚洲精品国产色婷婷电影| 人妻一区二区av| 免费观看性生交大片5| 国产精品.久久久| 能在线免费看毛片的网站| 在线天堂最新版资源| 插阴视频在线观看视频| 日本-黄色视频高清免费观看| 我要看黄色一级片免费的| 寂寞人妻少妇视频99o| 熟女人妻精品中文字幕| 一级,二级,三级黄色视频| 一边摸一边做爽爽视频免费| 久久99蜜桃精品久久| 香蕉精品网在线| 亚洲欧洲国产日韩| 国产在线一区二区三区精| 中国三级夫妇交换| 久久久a久久爽久久v久久| 欧美精品国产亚洲| 人妻 亚洲 视频| 欧美性感艳星| 十八禁网站网址无遮挡| 久久 成人 亚洲| 精品国产一区二区三区久久久樱花| 大香蕉97超碰在线| 亚洲av欧美aⅴ国产| 午夜激情福利司机影院| 国产精品偷伦视频观看了| 18禁动态无遮挡网站| 亚洲怡红院男人天堂| 中文字幕人妻熟人妻熟丝袜美| 亚洲综合色网址| 国产精品人妻久久久久久| 久久久久久久精品精品| 免费av不卡在线播放| 高清欧美精品videossex| 91久久精品电影网| 人妻系列 视频| 欧美日韩精品成人综合77777| 成年av动漫网址| 色吧在线观看| 精品视频人人做人人爽| 日韩强制内射视频| 亚洲精品美女久久av网站| 毛片一级片免费看久久久久| 亚洲成色77777| 美女cb高潮喷水在线观看| 午夜福利网站1000一区二区三区| 99热全是精品| 3wmmmm亚洲av在线观看| 亚洲国产精品国产精品| xxx大片免费视频| 国产淫语在线视频| 在线观看国产h片| 精品酒店卫生间| 中文字幕精品免费在线观看视频 | 免费高清在线观看视频在线观看| 成人二区视频| 亚洲国产精品专区欧美| 青春草视频在线免费观看| 制服人妻中文乱码| 国产欧美亚洲国产| 国语对白做爰xxxⅹ性视频网站| 成人毛片a级毛片在线播放| 一边摸一边做爽爽视频免费| 国产一区二区在线观看日韩| 丝袜喷水一区| 国产精品三级大全| 亚洲在久久综合| 最后的刺客免费高清国语| 男女啪啪激烈高潮av片| 中文字幕亚洲精品专区| 国产一区亚洲一区在线观看| 久久毛片免费看一区二区三区| 久久青草综合色| 99视频精品全部免费 在线| 精品人妻熟女av久视频| 国产 一区精品|